Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Gestational diabetes confers long-term type 2 diabetes risk

06 Feb 2020

The long-term risk of type 2 diabetes or impaired glucose tolerance is common in women with gestational diabetes, reports a new China study.

Researchers conducted a prospective nested case-cohort study including 121 women (mean age, 50.3 years) who were followed for a mean of 22.5 years. Oral glucose tolerance tests were conducted at 8, 15 and 22 years.

Twenty participants (16.9 percent) were identified to have type 2 diabetes over the follow-up period, with half being newly diagnosed. Forty-four had either diabetes or abnormal glucose tolerance, and 24 (20.3 percent) had metabolic syndrome.

Multiple logistic regression analysis revealed that a history of gestational diabetes mellitus or gestational impaired glucose tolerance (GDM/GIGT) significantly increased the risk of type 2 diabetes or abnormal glucose tolerance at follow-up, even after adjusting for potential confounders (odds ratio [OR], 2.78, 95 percent confidence interval [CI], 1.18–6.55; p=0.02).

Longitudinal assessment was possible in 943 women. At the 8-year follow-up, 40.3 percent of the GDM/GIGT participants were dysglycaemic, as opposed to only 17.7 percent of those with normal glucose tolerance (p=0.001). This gap remained significant even after 22 years of follow-up (52.6 percent vs 30.0 percent; p=0.025). Two-hour glucose levels were similarly longitudinally elevated in GDM/GIGT participants.

“There is a need to raise awareness concerning this at-risk population and to implement active surveillance to prevent associated morbidity and mortality,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.